Eli Lilly touts early demand for high-stakes diabetes launch Mounjaro: analysts

After snaring approval in May, Eli Lilly’s closely watched diabetes med tirzepatide—now christened Mounjaro—is said to be “tracking at the highest end” of the company’s demand expectations.